Aug 23, 2022

Remedium Bio closes successful $2.3m expanded seed raise

Posted by in categories: biotech/medical, life extension

Remedium Bio has announced that it has closed more than $2.3m in its expanded seed round financing. Funding from the raise is being used to study Remedium’s lead product, a single-injection gene therapy potentially capable of reversing cartilage loss; this research is being conducted in collaboration with scientists from Tufts University School of Medicine who are engaged in researching rheumatic disorders.

The financing was led by Sherwood Ventures and included participation from, LongevityTech. Fund, Primo Medical Group, Angel Star Ventures, Apis Health Angels, MicroVentures, and Guindy Alumni Angels.

Longevity. Technology: Remedium’s pipeline includes therapeutic indications in osteoarthritis, diabetes, stroke and other large unmet clinical needs.

Comments are closed.